684 studies found for:    trastuzumab
Show Display Options
Download search resultsDownload the search results for:
trastuzumab (684 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla];   Drug: Trastuzumab;   Drug: Docetaxel
2 Recruiting Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Conditions: Bone Metastases;   HER2-positive Breast Cancer;   Liver Metastases;   Lung Metastases;   Recurrent Breast Cancer;   Soft Tissue Metastases;   Stage IV Breast Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Biological: trastuzumab;   Radiation: copper Cu 64-DOTA-trastuzumab;   Biological: ado-trastuzumab emtansine;   Other: laboratory biomarker analysis
3 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
4 Completed A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Condition: Healthy
Interventions: Biological: PF-05280014;   Biological: Herceptin
5 Active, not recruiting Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Condition: Metastatic Breast Cancer
Interventions: Drug: U3-1287;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
6 Recruiting Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Condition: Esophageal Carcinoma
Intervention: Drug: Pertuzumab, trastuzumab
7 Recruiting A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).
Condition: Brest Cancer
Interventions: Drug: Trastuzumab subcutaneous inyection vial;   Device: Trastuzumab subcutaneous device administration
8 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
9 Recruiting NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Condition: HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab
Interventions: Drug: BKM120;   Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Placebo
10 Completed 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
Condition: Breast Cancer
Intervention: Other: Imaging with 89Zr-trastuzumab PET
11 Recruiting 64Cu DOTA-Trastuzumab PET in Studying Patients With Gastric Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Gastric Cancer;   Stage IA Gastric Cancer;   Stage IB Gastric Cancer;   Stage IIA Gastric Cancer;   Stage IIB Gastric Cancer;   Stage IIIA Gastric Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Gastric Cancer
Interventions: Radiation: copper Cu 64-DOTA-trastuzumab;   Device: positron emission tomography;   Other: laboratory biomarker analysis
12 Completed
Has Results
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001
13 Completed Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Condition: Solid Tumors
Intervention: Radiation: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
14 Recruiting Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Condition: Breast Cancer
Intervention: Radiation: Trastuzumab
15 Completed
Has Results
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab emtansine
16 Active, not recruiting Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: PF03512676;   Other: Correlative Studies
17 Terminated Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
Condition: Metastatic Breast Cancer
Interventions: Drug: G-CSF;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: saline
18 Terminated Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Conditions: Cardiac Toxicity;   Inflammatory Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Drug: paclitaxel;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
19 Active, not recruiting Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: nab-paclitaxel;   Drug: trastuzumab
20 Terminated Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma;   Recurrent Salivary Gland Cancer;   Salivary Gland Acinic Cell Tumor;   Salivary Gland Adenocarcinoma;   Salivary Gland Poorly Differentiated Carcinoma;   Stage IVA Salivary Gland Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer
Interventions: Biological: trastuzumab;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years